Atossa Therapeutics, a clinical-stage biopharmaceutical company specializing in innovative oncology treatments, has partnered with Quantum Leap Healthcare Collaborative to launch a groundbreaking clinical study. This trial aims to evaluate the potential of Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO), a prominent cyclin-dependent kinase (CDK) 4/6 inhibitor developed by Eli Lilly and Company. By focusing on women with ER+/HER2- breast cancer, this study endeavors to address significant unmet medical needs in the field of breast cancer treatment.
Facts:Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative announce the initiation of a new clinical trial.2. The study will assess the effectiveness of Atossa’s (Z)-endoxifen in combination with Eli Lilly’s abemaciclib (VERZENIO) in women with ER+/HER2- breast cancer.3. Atossa Therapeutics is a clinical-stage biopharmaceutical company focusing on developing innovative therapies for breast cancer.4. Abemaciclib, a CDK 4/6 inhibitor, is known for its effectiveness in breast cancer treatment.5. ER+/HER2- breast cancer is a common subtype that lacks targeted treatment options.
Assessment of Impact on Atossa Therapeutics:The collaboration between Atossa Therapeutics and Quantum Leap Healthcare Collaborative represents a significant milestone for the company. By venturing into a clinical trial that explores the combination therapy of (Z)-endoxifen with VERZENIO, Atossa demonstrates its commitment to developing groundbreaking treatments for breast cancer patients, particularly those dealing with ER+/HER2- subtypes. By leveraging Eli Lilly’s established CDK 4/6 inhibitor, this study allows Atossa Therapeutics to explore the potential synergistic effects of combination therapy, potentially offering a more effective treatment approach.
Moreover, entering the I-SPY 2 Clinical Trial, a widely recognized and respected platform for assessing investigational therapies, showcases Atossa Therapeutics as a player in the oncology field. The company’s focus on breast cancer, an area with significant unmet medical needs, also positions them favorably in providing solutions for patients and healthcare providers worldwide.
Comments